AC Immune SAの価格/簿価
AC Immune SAの価格/簿価は何ですか。
AC Immune SAの価格/簿価は0.86です。
価格/簿価の定義は何ですか。
株価純資産倍率は、会社の株価と1株当たりの簿価との比率を表します。
The price to book ratio, or P/B ratio, is a financial ratio used to compare a company's current market price to its book value. It is also sometimes known as a market to book ratio or price to equity ratio. The calculation of a price to book ratio can be performed in two ways. It can be calculated as the company's market capitalization divided by the company's total book value from its balance sheet. It can also be calculated using per-share values and dividing a company's current share price by the book value per share (i.e. its book value divided by the number of outstanding shares).
The P/B ratio varies between industries. The industries that require more infrastructure capital (for each dollar of profit) will usually trade at P/B ratios much lower than, for example, consulting firms. P/B ratios are commonly used to compare banks, because most assets and liabilities of banks are constantly valued at market values. A higher P/B ratio implies that investors expect management to create more value from a given set of assets, all else equal (and/or that the market value of the firm's assets is significantly higher than their accounting value).
P/B ratios do not, however, directly provide any information on the ability of the firm to generate profits or cash for shareholders. This ratio also gives some idea of whether an investor is paying too much for what would be left if the company went bankrupt immediately. For companies in distress, the book value is usually calculated without the intangible assets that would have no resale value. In such cases, P/B should also be calculated on a "diluted" basis, because stock options may well vest on sale of the company or change of control or firing of management.
NASDAQのセクタHealth Careにおける価格/簿価の企業と比べるAC Immune SA
AC Immune SAは何をしますか。
ac immune is a clinical-stage swiss-based biopharmaceutical company, listed on nasdaq, which aims to become a global leader in precision medicine for neurodegenerative diseases. the company designs, discovers and develops therapeutic as well as diagnostic products intended to prevent and modify diseases caused by misfolding proteins. ac immune’s two proprietary technology platforms create antibodies, small molecules and vaccines designed to address a broad spectrum of neurodegenerative indications, such as alzheimer’s disease (ad). the company’s pipeline features nine therapeutic and three diagnostic product candidates – with five product candidates currently in clinical trials. the most advanced of these is crenezumab, a humanized anti-amyloid-β monoclonal igg4 antibody that targets monomeric and aggregated forms of amyloid-β, with highest affinity for neurotoxic oligomers. crenezumab is currently in two phase 3 clinical studies for ad, under a global program conducted by the collabor
AC Immune SAと類似の価格/簿価
- RenaissanceRe Ltdの価格/簿価は0.86です。
- Atrium European Real Estateの価格/簿価は0.86です。
- Modern Dentalの価格/簿価は0.86です。
- Octopus AIM VCTの価格/簿価は0.86です。
- Central Securities Corpの価格/簿価は0.86です。
- Phoenix Spree Deutschlandの価格/簿価は0.86です。
- AC Immune SAの価格/簿価は0.86です。
- Booktopiaの価格/簿価は0.86です。
- IAGの価格/簿価は0.86です。
- Panoro Mineralsの価格/簿価は0.86です。
- Success Universeの価格/簿価は0.86です。
- Northern 3 VCTの価格/簿価は0.86です。
- National Services Reunited Corpの価格/簿価は0.86です。